In return Sage gets $1.525 billion upfront – $875 million in cash and a $650 million equity investment – as well as potential milestones of $1.6 billion if both drugs meet their development ...
Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE – Get Free Report) have been given a consensus rating of “Hold” by the nineteen ratings firms that are currently covering the firm, Marketbeat ...
Sage Therapeutics, Inc. (NASDAQ:SAGE – Get Free Report) has been given a consensus recommendation of “Hold” by the nineteen ratings firms that are currently covering the stock, MarketBeat ...
SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in providing solutions to brain health medicines. It focuses on diseases and disorders of the brain. Its products include ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback